Kairos Pharma (KAPA) - 75.36% Below 52-Week High: Buy or Wait?

Stock Details

Kairos Pharma, Ltd. (KAPA), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the ASE.Currently, the stock is trading at $0.52. Over the past 52 weeks, it has ranged between $0.40 and $2.11. This places the current price at 24.6% of its 52-week high and 30.0% above its 52-week low. Recent trading volume was recorded at 142,689. The 14-day Relative Strength Index (RSI) stands at 49.99, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $0.58 by 10.34%. Similarly, it is below its 200-day moving average of $0.86 by 39.53%. The MACD histogram is 0.00, indicating neutral momentum (MACD Line: -0.02, Signal Line: -0.03). There are currently 2 active alerts set for KAPA by users.

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-0.81

Price to Book

1.79

EV/EBITDA

-1.37

EPS (TTM)

-$0.30

Q:How is KAPA valued relative to its earnings and growth?

Valuation data is not available for this stock.

Q:What is KAPA's risk profile compared to the market?

Risk profile data is not available for this stock.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-5,836,000

Return on Equity

-93.84%

Return on Assets

-54.78%

Q:How profitable and efficient is KAPA's business model?

Profitability metrics are not available for this stock.

Q:What are KAPA's recent growth trends?

Growth data is not available for this stock.

Company Size & Market

Market Cap

$11.7M

Shares Outstanding

21.41M

Book Value/Share

$0.31

Asset Type

EQUITY

Q:What is KAPA's market capitalization and position?

Kairos Pharma, Ltd. has a market capitalization of $11.7M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 21.41M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.

Q:How does KAPA's price compare to its book value?

Kairos Pharma, Ltd.'s book value per share is $0.31, while the current stock price is $0.52, resulting in a price-to-book (P/B) ratio of 1.70. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$8.00

1438.46% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

Q:How reliable are analyst predictions for KAPA?

3 analysts cover KAPA with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $8.00 implies 1438.5% upside, but targets are often adjusted to follow price moves rather than predict them.

Q:What is the Wall Street consensus on KAPA?

Current analyst recommendations:1 Strong Buy, 2 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: May 23, 2026, 02:14 AM

Technical Indicators

RSI (14-day)

49.99

Neutral

50-Day Moving Average

$0.58

-10.34% below MA-50

200-Day Moving Average

$0.86

-39.53% below MA-200

MACD Line

-0.02

MACD Signal

-0.03

MACD Histogram

N/A

Neutral

Q:What does KAPA's RSI value tell investors?

The RSI (Relative Strength Index) for KAPA is currently 49.99, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.

Q:How should traders interpret KAPA's MACD and moving average crossovers?

MACD analysis shows the MACD line at -0.02 above the signal line at -0.03, with histogram at 0.00. This bearish crossover indicates downward pressure. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($0.58) is below the 200-day MA ($0.86), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: May 23, 2026, 12:37 AM

Condition	Threshold	Created At
Price rises above	$0.80	Mar 6, 2026, 01:36 AM
Volume change	300%	Mar 6, 2026, 01:36 AM

Condition

Threshold

Created At

Price rises above

$0.80

Mar 6, 2026, 01:36 AM

Volume change

300%